🚀 VC round data is live in beta, check it out!
Bayer Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bayer and similar public comparables like Sun Pharma, argenx, Lonza Group, Haleon and more.
Bayer Overview
About Bayer
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
Founded
1863
HQ
Employees
92.8K
Website
Financials (LTM)
EV
$84B
Bayer Financials
Bayer reported last 12-month revenue of $53B and EBITDA of $11B.
In the same LTM period, Bayer generated $31B in gross profit, $11B in EBITDA, and $5B in net income.
Revenue (LTM)
Bayer P&L
In the most recent fiscal year, Bayer reported revenue of $53B and EBITDA of $11B.
Bayer expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $53B | XXX | $53B | XXX | XXX | XXX |
| Gross Profit | $31B | XXX | $31B | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $11B | XXX | $11B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $5B | XXX | $6B | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $33B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bayer Stock Performance
Bayer has current market cap of $46B, and enterprise value of $84B.
Market Cap Evolution
Bayer's stock price is $46.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $84B | $46B | -0.2% | XXX | XXX | XXX | $5.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBayer Valuation Multiples
Bayer trades at 1.6x EV/Revenue multiple, and 7.5x EV/EBITDA.
EV / Revenue (LTM)
Bayer Financial Valuation Multiples
As of March 14, 2026, Bayer has market cap of $46B and EV of $84B.
Equity research analysts estimate Bayer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bayer has a P/E ratio of 8.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46B | XXX | $46B | XXX | XXX | XXX |
| EV (current) | $84B | XXX | $84B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBIT | 11.2x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | 2.7x | XXX | XXX | XXX |
| P/E | 8.4x | XXX | 8.2x | XXX | XXX | XXX |
| EV/FCF | 50.0x | XXX | 21.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bayer Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bayer Margins & Growth Rates
Bayer's revenue in the last 12 month declined by (1%).
Bayer's revenue per employee in the last FY averaged $0.6M.
Bayer's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bayer's rule of X is 19% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bayer Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (1%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | (2%) | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bayer Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| argenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Lonza Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Haleon | XXX | XXX | XXX | XXX | XXX | XXX |
| Galderma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bayer M&A Activity
Bayer acquired XXX companies to date.
Last acquisition by Bayer was on XXXXXXXX, XXXXX. Bayer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bayer
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBayer Investment Activity
Bayer invested in XXX companies to date.
Bayer made its latest investment on XXXXXXXX, XXXXX. Bayer invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bayer
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bayer
| When was Bayer founded? | Bayer was founded in 1863. |
| Where is Bayer headquartered? | Bayer is headquartered in Germany. |
| How many employees does Bayer have? | As of today, Bayer has over 92K employees. |
| Is Bayer publicly listed? | Yes, Bayer is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Bayer? | Bayer trades under BAYN ticker. |
| When did Bayer go public? | Bayer went public in 1953. |
| Who are competitors of Bayer? | Bayer main competitors are Sun Pharma, argenx, Lonza Group, Haleon. |
| What is the current market cap of Bayer? | Bayer's current market cap is $46B. |
| What is the current revenue of Bayer? | Bayer's last 12 months revenue is $53B. |
| What is the current revenue growth of Bayer? | Bayer revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of Bayer? | Current revenue multiple of Bayer is 1.6x. |
| Is Bayer profitable? | Yes, Bayer is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bayer? | Bayer's last 12 months EBITDA is $11B. |
| What is Bayer's EBITDA margin? | Bayer's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Bayer? | Current EBITDA multiple of Bayer is 7.5x. |
| What is the current FCF of Bayer? | Bayer's last 12 months FCF is $2B. |
| What is Bayer's FCF margin? | Bayer's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Bayer? | Current FCF multiple of Bayer is 50.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.